J
Jeffrey S. Wefel
Researcher at University of Texas MD Anderson Cancer Center
Publications - 44
Citations - 11703
Jeffrey S. Wefel is an academic researcher from University of Texas MD Anderson Cancer Center. The author has contributed to research in topics: Medicine & Cognition. The author has an hindex of 22, co-authored 25 publications receiving 9820 citations. Previous affiliations of Jeffrey S. Wefel include Medical College of Wisconsin & University of Texas at Austin.
Papers
More filters
Journal ArticleDOI
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert,James J. Dignam,Terri S. Armstrong,Terri S. Armstrong,Jeffrey S. Wefel,Deborah T. Blumenthal,Michael A. Vogelbaum,Howard Colman,Arnab Chakravarti,Stephanie L. Pugh,Minhee Won,Robert Jeraj,Paul D. Brown,Kurt A. Jaeckle,David Schiff,Volker W. Stieber,David Brachman,Maria Werner-Wasik,Ivo W. Tremont-Lukats,Erik P. Sulman,Kenneth Aldape,Walter J. Curran,Minesh P. Mehta +22 more
TL;DR: First-line use of bevacizumab did not improve overall survival in patients with newly diagnosed glioblastoma, and progression-free survival was prolonged but did not reach the prespecified improvement target.
Journal ArticleDOI
Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial.
Eric L. Chang,Jeffrey S. Wefel,Kenneth R. Hess,Pamela K. Allen,Frederick F. Lang,David G. Kornguth,Rebecca Arbuckle,J. Michael Swint,Almon S. Shiu,Moshe H. Maor,Christina A. Meyers +10 more
TL;DR: Patients treated with SRS plus WBRT were at a greater risk of a significant decline in learning and memory function by 4 months compared with the group that received SRS alone, and patients treatment with a combination of SRS and close clinical monitoring was recommended as the preferred treatment strategy.
Journal ArticleDOI
Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial
Mark R. Gilbert,Meihua Wang,Kenneth Aldape,Roger Stupp,Monika E. Hegi,Kurt A. Jaeckle,Terri S. Armstrong,Terri S. Armstrong,Jeffrey S. Wefel,Minhee Won,Deborah T. Blumenthal,Anita Mahajan,Christopher J. Schultz,Sara Erridge,Brigitta G. Baumert,Kristen I. Hopkins,Tzahala Tzuk-Shina,Paul D. Brown,Arnab Chakravarti,Walter J. Curran,Minesh P. Mehta +20 more
TL;DR: This study did not demonstrate improved efficacy for DD temozolomide for newly diagnosed GBM, regardless of methylation status, but it did confirm the prognostic significance of MGMT methylation.
Journal ArticleDOI
Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebo-controlled trial.
Paul D. Brown,Stephanie L. Pugh,Nadia N. Laack,Jeffrey S. Wefel,Deepak Khuntia,Christina A. Meyers,Ali Choucair,Sherry Fox,John H. Suh,David Roberge,V.S. Kavadi,Søren M. Bentzen,Minesh P. Mehta,Deborah Watkins-Bruner +13 more
TL;DR: Overall, patients treated with memantine had better cognitive function over time; specifically, memantine delayed time to cognitive decline and reduced the rate of decline in memory, executive function, and processing speed in patients receiving WBRT.
Journal ArticleDOI
International Cognition and Cancer Task Force recommendations to harmonise studies of cognitive function in patients with cancer
TL;DR: The International Cognition and Cancer Task Force (ICCTF) developed recommendations for a core set of neuropsychological tests, common criterion for defining cognitive impairment and cognitive changes, and common approaches to improve the homogeneity of study methods as discussed by the authors.